Skip to main content

LIGHTPATH TECHNOLOGIES INC

For the period ended Mar 31, 2025. Filed May 20, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 20, 2025

LPTH$7.99-0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

Nine Months Ended March 31,
2025 · 2024
Cash flows from operating activities:
Net loss$(7,817,202)$(5,653,573)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization3,356,7522,985,850
Interest from amortization of loan issuance costs161,905-
Loss on extinguishment of debt418,502-
Change in fair value of warrant liability(870,554)-
Loss on disposal of property and equipment80,50513,248
Stock-based compensation on stock options, RSUs & RSAs, net745,155763,258
Provision for credit losses(3,014)(4,422)
Change in operating lease assets and liabilities(91,582)47,693
Inventory write-offs to allowance135,62595,539
Deferred taxes(2,368)8,573
Changes in operating assets and liabilities, net of acquisitions:
Trade accounts receivable(822,043)1,766,594
Other current assets73,362(419,797)
Inventories(1,206,340)725,460
Prepaid expenses and deposits(360,439)95,900
Accounts payable and accrued liabilities520,28932,020
Net cash (used in) provided by operating activities(5,681,447)456,343
Cash flows from investing activities:
Purchase of property and equipment(580,726)(1,892,660)
Proceeds from sale of equipment10,648-
Proceeds from sale-leaseback of equipment-364,710
Acquisition of G5(20,250,011)-
Acquisition of Visimid, net of cash acquired-(847,141)
Net cash used in investing activities(20,820,089)(2,375,091)
Cash flows from financing activities:
Proceeds from exercise of stock options3,175-
Proceeds from sale of common stock from Employee Stock Purchase Plan14,38539,677
Proceeds from issuance of common stock under public equity placement, net of fees-98,208
Proceeds from issuance of common stock under private equity placement, net of fees437,725-
Proceeds from issuance of preferred stock under private equity placement, net of fees18,842,138-
Proceeds from issuance of warrants under private equity placement4,620,561-
Deferred payment for acquisition of Visimid(125,000)-
Borrowings on loans payable6,659,596142,853
Loan issuance costs(597,465)-
Payments on loans payable(149,118)(2,262,798)
Repayment of finance lease obligations(133,711)(87,610)
Net cash provided by (used in) financing activities29,572,286(2,069,670)
Effect of exchange rate on cash and cash equivalents(72,133)2,880
Change in cash, cash equivalents and restricted cash2,998,617(3,985,538)
Cash, cash equivalents and restricted cash, beginning of period3,480,2687,144,490
Cash, cash equivalents and restricted cash, end of period$6,478,885$3,158,952
Supplemental disclosure of cash flow information:
Interest paid in cash$66,136$161,676
Income taxes paid$118,016$120,787
Supplemental disclosure of non-cash investing & financing activities:
Purchase of equipment through finance lease arrangements$93,048$391,107
Issuance of common stock for acquisition of Visimid$713,946$486,054
Issuance of common stock for acquisition of G5$4,872,068$-
Accrual of earnout consideration for acquisition of G5$2,501,000$-
Extinguishment of debt in exchange for common stock, preferred stock warrants and a note$3,057,110$-

The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.